Designer benzodiazepines: new challenges and treatment options

Peter D. Maskell, Nathan E. Wilson

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Abstract

    New Psychoactive Substance (NPS) benzodiazepines (AKA designer benzodiazepines) emerged in Europe around 2007, but were first detected and identified in death cases in 2010 in the USA (Bailey et al. 2010) and 2011 in the UK (Maskell et al. 2011a). Since the first NPS benzodiazepines emerged another 20 are being monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), leading to concern that the abuse of NPS benzodiazepines may become a significant global problem. This chapter looks at NPS benzodiazepines, their pharmacology, potency, prevalence, use, abuse, potential poly-pharmacy, risk of hospitalisation, detection in the clinical setting and finally treatment of overdose.
    Original languageEnglish
    Title of host publicationHandbook of novel psychoactive substances
    Subtitle of host publicationwhat clinicians should know about NPS
    EditorsOrnella Corazza, Andrew Roman-Urrestarazu
    PublisherRoutledge
    Chapter19
    Pages342-363
    Number of pages22
    Edition1st
    ISBN (Electronic)9781315158082
    ISBN (Print)9781138068308, 9781138068292
    Publication statusPublished - 19 Oct 2018

    Fingerprint

    Benzodiazepines
    Therapeutics
    Drug Monitoring
    Substance-Related Disorders
    Hospitalization
    Pharmacology

    Cite this

    Maskell, P. D., & Wilson, N. E. (2018). Designer benzodiazepines: new challenges and treatment options . In O. Corazza, & A. Roman-Urrestarazu (Eds.), Handbook of novel psychoactive substances : what clinicians should know about NPS (1st ed., pp. 342-363). Routledge.
    Maskell, Peter D. ; Wilson, Nathan E. / Designer benzodiazepines : new challenges and treatment options . Handbook of novel psychoactive substances : what clinicians should know about NPS. editor / Ornella Corazza ; Andrew Roman-Urrestarazu. 1st. ed. Routledge, 2018. pp. 342-363
    @inbook{f6c49e576f61482c91c82f4595dd70c8,
    title = "Designer benzodiazepines: new challenges and treatment options",
    abstract = "New Psychoactive Substance (NPS) benzodiazepines (AKA designer benzodiazepines) emerged in Europe around 2007, but were first detected and identified in death cases in 2010 in the USA (Bailey et al. 2010) and 2011 in the UK (Maskell et al. 2011a). Since the first NPS benzodiazepines emerged another 20 are being monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), leading to concern that the abuse of NPS benzodiazepines may become a significant global problem. This chapter looks at NPS benzodiazepines, their pharmacology, potency, prevalence, use, abuse, potential poly-pharmacy, risk of hospitalisation, detection in the clinical setting and finally treatment of overdose.",
    author = "Maskell, {Peter D.} and Wilson, {Nathan E.}",
    year = "2018",
    month = "10",
    day = "19",
    language = "English",
    isbn = "9781138068308",
    pages = "342--363",
    editor = "Ornella Corazza and Andrew Roman-Urrestarazu",
    booktitle = "Handbook of novel psychoactive substances",
    publisher = "Routledge",
    address = "United Kingdom",
    edition = "1st",

    }

    Maskell, PD & Wilson, NE 2018, Designer benzodiazepines: new challenges and treatment options . in O Corazza & A Roman-Urrestarazu (eds), Handbook of novel psychoactive substances : what clinicians should know about NPS. 1st edn, Routledge, pp. 342-363.

    Designer benzodiazepines : new challenges and treatment options . / Maskell, Peter D.; Wilson, Nathan E.

    Handbook of novel psychoactive substances : what clinicians should know about NPS. ed. / Ornella Corazza; Andrew Roman-Urrestarazu. 1st. ed. Routledge, 2018. p. 342-363.

    Research output: Chapter in Book/Report/Conference proceedingChapter

    TY - CHAP

    T1 - Designer benzodiazepines

    T2 - new challenges and treatment options

    AU - Maskell, Peter D.

    AU - Wilson, Nathan E.

    PY - 2018/10/19

    Y1 - 2018/10/19

    N2 - New Psychoactive Substance (NPS) benzodiazepines (AKA designer benzodiazepines) emerged in Europe around 2007, but were first detected and identified in death cases in 2010 in the USA (Bailey et al. 2010) and 2011 in the UK (Maskell et al. 2011a). Since the first NPS benzodiazepines emerged another 20 are being monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), leading to concern that the abuse of NPS benzodiazepines may become a significant global problem. This chapter looks at NPS benzodiazepines, their pharmacology, potency, prevalence, use, abuse, potential poly-pharmacy, risk of hospitalisation, detection in the clinical setting and finally treatment of overdose.

    AB - New Psychoactive Substance (NPS) benzodiazepines (AKA designer benzodiazepines) emerged in Europe around 2007, but were first detected and identified in death cases in 2010 in the USA (Bailey et al. 2010) and 2011 in the UK (Maskell et al. 2011a). Since the first NPS benzodiazepines emerged another 20 are being monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), leading to concern that the abuse of NPS benzodiazepines may become a significant global problem. This chapter looks at NPS benzodiazepines, their pharmacology, potency, prevalence, use, abuse, potential poly-pharmacy, risk of hospitalisation, detection in the clinical setting and finally treatment of overdose.

    M3 - Chapter

    SN - 9781138068308

    SN - 9781138068292

    SP - 342

    EP - 363

    BT - Handbook of novel psychoactive substances

    A2 - Corazza, Ornella

    A2 - Roman-Urrestarazu, Andrew

    PB - Routledge

    ER -

    Maskell PD, Wilson NE. Designer benzodiazepines: new challenges and treatment options . In Corazza O, Roman-Urrestarazu A, editors, Handbook of novel psychoactive substances : what clinicians should know about NPS. 1st ed. Routledge. 2018. p. 342-363